

Insuficiencia renal en la cirrosis

Referencias

1. Ginès P, Cárdenas A, Schrier RW. Liver disease and the kidney. In: Schrier RW, ed. *Diseases of the kidney and urinary tract*. 8th ed. Philadelphia: Lippincott Williams & Wilkins, 2007:2179-205.
2. Moreau R, Lebrec D. Acute renal failure in patients with cirrhosis: perspectives in the age of MELD. *Hepatology* 2003;37:233-43.
3. Nair S, Verma S, Thuluvath PJ. Pretransplant renal function predicts survival in patients undergoing orthotopic liver transplantation. *Hepatology* 2002;35:1179-85.
4. Gonwa TA, Klintmalm GB, Levy M, Jennings LS, Goldstein RM, Husberg BS. Impact of pretransplant renal function on survival after liver transplantation. *Transplantation* 1995;59:361-5.
5. Wiesner R, Edwards E, Freeman R, et al. Model for End-Stage Liver Disease (MELD) and allocation of donor livers. *Gastroenterology* 2003;124:91-6.
6. Gonwa TA, McBride MA, Anderson K, Mai ML, Wadei H, Ahsan N. Continued influence of preoperative renal function on outcome of orthotopic liver transplant (OLT) in the US: where will MELD lead us? *Am J Transplant* 2006;6: 2651-9.
7. Kamath PS, Kim WR. The Model for End-Stage Liver Disease (MELD). *Hepatology* 2007;45:797-805.
8. Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodés J. Peripheral arterial vasodilatation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. *Hepatology* 1988;8:1151-7.
9. Arroyo V, Ginès P, Gerbes AL, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. *Hepatology* 1996;23:164-76.
10. Martin PY, Ginès P, Schrier RW. Nitric oxide as a mediator of hemodynamic abnormalities and sodium and water retention in cirrhosis. *N Engl J Med* 1998;339:533-41.
11. Bosch J, Abraldes JG, Berzigotti A, Garcia-Pagan JC. Portal hypertension and gastrointestinal bleeding. *Semin Liver Dis* 2008;28:3-25.
12. Ros J, Clària J, To-Figueras J, et al. Endogenous cannabinoids: a new system involved in the homeostasis of arterial pressure in experimental cirrhosis in the rat. *Gastroenterology* 2002;122:85-93.
13. Ruiz-del-Arbol L, Monescillo A, Arocena C, et al. Circulatory function and hepatorenal syndrome in cirrhosis. *Hepatology* 2005;42:439-47.
14. Wiest R, Das S, Cadelina G, Garcia-Tsao G, Milstien S, Groszmann RJ. Bacterial translocation in cirrhotic rats stimulates eNOS-derived NO production and impairs mesenteric vascular contractility. *J Clin Invest* 1999;104:1223-33.
15. Wiest R, Garcia-Tsao G. Bacterial translocation (BT) in cirrhosis. *Hepatology* 2005;41:422-33.
16. Albillos A, de la Hera A, González M, et al. Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement. *Hepatology* 2003;37:208-17.
17. Francés R, Zapater P, González Navajas JM, et al. Bacterial DNA in patients with cirrhosis and noninfected ascites mimics the soluble immune response established in patients with spontaneous bacterial peritonitis. *Hepatology* 2008;47:978-85.
18. Chin-Dusting JP, Rasaratnam B, Jennings GL, Dudley FJ. Effect of fluoroquinolone on the enhanced nitric oxide-induced peripheral vasodilation seen in cirrhosis. *Ann Intern Med* 1997;127:985-8.
19. Rasaratnam B, Kaye D, Jennings G, Dudley F, Chin-Dusting J. The effect of selective intestinal decontamination on the hyperdynamic circulatory state in cirrhosis: a randomized trial. *Ann Intern Med* 2003;139:186-93.
20. Wong F, Bernardi M, Balk R, et al. Sepsis in cirrhosis: report on the 7th meeting of the International Ascites Club. *Gut* 2005;54:718-25.
21. Thabut D, Massard J, Gangloff A, et al. Model for End-Stage Liver Disease score and systemic inflammatory response are major prognostic factors in patients with cirrhosis and acute functional renal failure. *Hepatology* 2007;46:1872-82.
22. Cárdenas A, Ginès P, Uriz J, et al. Renal failure after upper gastrointestinal bleeding in cirrhosis: incidence, clinical course, predictive factors, and short-term prognosis. *Hepatology* 2001;34:671-6.

23. Hampel H, Bynum GD, Zamora E, El-Serag HB. Risk factors for the development of renal dysfunction in hospitalized patients with cirrhosis. *Am J Gastroenterol* 2001;96:2206-10.
24. Terg R, Gadano A, Cartier M, et al. Serum creatinine and bilirubin predict renal failure and mortality in patients with spontaneous bacterial peritonitis: a retrospective study. *Liver Int* 2009;29:415-9.
25. Bories PN, Campillo B, Azaou L, Scherman E. Long-lasting NO overproduction in cirrhotic patients with spontaneous bacterial peritonitis. *Hepatology* 1997;25:1328-33.
26. Grangé JD, Amiot X. Nitric oxide and renal function in cirrhotic patients with ascites: from pathophysiology to practice. *Eur J Gastroenterol Hepatol* 2004;16:567-70.
27. Terra C, Guevara M, Torre A, et al. Renal failure in patients with cirrhosis and sepsis unrelated to spontaneous bacterial peritonitis: value of MELD score. *Gastroenterology* 2005;129:1944-53.
28. Fasolato S, Angeli P, Dallagnese L, et al. Renal failure and bacterial infections in patients with cirrhosis: epidemiology and clinical features. *Hepatology* 2007;45:223-9.
29. Salerno F, Badalamenti S. Drug-induced renal failure in cirrhosis. In: Ginès P, Arroyo V, Rodés J, Schrier RW, eds. *Ascites and renal dysfunction in liver disease*. 2nd ed. Malden, MA: Blackwell, 2005:372-82.
30. Meyers CM, Seeff LB, Stehman-Breen CO, Hoofnagle JH. Hepatitis C and renal disease: an update. *Am J Kidney Dis* 2003;42:631-57.
31. Poole BD, Schrier RW. Glomerular disease in cirrhosis. In: Ginès P, Arroyo V, Rodés J, Schrier RW, eds. *Ascites and renal dysfunction in liver disease*. 2nd ed. Malden, MA: Blackwell, 2005:360-71.
32. Ginès A, Escorsell A, Ginès P, et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. *Gastroenterology* 1993;105:229-36.
33. Salerno F, Gerbes A, Ginès P, Wong F, Arroyo V. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. *Gut* 2007;56:1310-8.
34. Skluzacek PA, Szewc RG, Nolan CR III, Riley DJ, Lee S, Pergola PE. Prediction of GFR in liver transplant candidates. *Am J Kidney Dis* 2003;42:1169-76.
35. MacAulay J, Thompson K, Kiberd BA, Barnes DC, Peltekian KM. Serum creatinine in patients with advanced liver disease is of limited value for identification of moderate renal dysfunction: are the equations for estimating renal function better? *Can J Gastroenterol* 2006;20:521-6.
36. Proulx NL, Akbari A, Garg AX, Rostom A, Jaffey J, Clark HD. Measured creatinine clearance from timed urine collections
37. substantially overestimates glomerular filtration rate in patients with liver cirrhosis: a systematic review and individual patient meta-analysis. *Nephrol Dial Transplant* 2005;20:1617-22.
38. Moore KP, Wong F, Ginès P, et al. The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. *Hepatology* 2003;38:258-66.
39. Bataller R, Ginès P, Guevara M, Arroyo V. Hepatorenal syndrome. *Semin Liver Dis* 1997;17:233-47.
40. Caregaro L, Menon F, Angeli P, et al. Limitations of serum creatinine level and creatinine clearance as filtration markers in cirrhosis. *Arch Intern Med* 1994;154:201-5.
41. Sherman DS, Fish DN, Teitelbaum I. Assessing renal function in cirrhotic patients: problems and pitfalls. *Am J Kidney Dis* 2003;41:269-78.
42. Mehta RL, Kellum JA, Shah SV, et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. *Crit Care* 2007;11(2):R31.
43. Garcia-Tsao G, Parikh CR, Viola A. Acute kidney injury in cirrhosis. *Hepatology* 2008;48:2064-77.
44. Levey AS, Coresh J, Balk E, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. *Ann Intern Med* 2003;139:137-47. [Erratum, *Ann Intern Med* 2003;139:605.]
45. Han WK, Waikar SS, Johnson A, et al. Urinary biomarkers in the early diagnosis of acute kidney injury. *Kidney Int* 2008; 73:863-9.
46. Tandon P, Garcia-Tsao G. Bacterial infections, sepsis, and multiorgan failure in cirrhosis. *Semin Liver Dis* 2008;28:26-42.
47. Angeli P, Merkel C. Pathogenesis and management of hepatorenal syndrome in patients with cirrhosis. *J Hepatol* 2008;48: Suppl 1:S93-S103.
48. Grewal P, Martin P. Pretransplant management of the cirrhotic patient. *Clin Liver Dis* 2007;11:431-49.
49. Tsai MH, Peng YS, Chen YC, et al. Adrenal insufficiency in patients with cirrhosis, severe sepsis and septic shock. *Hepatology* 2006;43:673-81.
50. Fernández J, Escorsell A, Zabalza M, et al. Adrenal insufficiency in patients with cirrhosis and septic shock: effect of treatment with hydrocortisone on survival. *Hepatology* 2006;44:1288-95.
51. Garcia-Tsao G. Current management of the complications of cirrhosis and portal hypertension: variceal hemorrhage, ascites, and spontaneous bacterial peritonitis. *Gastroenterology* 2001;120:726-48.
52. Martin P, Fabrizi F. Hepatitis C virus and kidney disease. *J Hepatol* 2008;49:613-24.

53. McCullough PA. Contrast-induced acute kidney injury. *J Am Coll Cardiol* 2008;51:1419-28. [Erratum, *J Am Coll Cardiol* 2008;51:2197.]
54. McCormick PA, Donnelly C. Management of hepatorenal syndrome. *Pharmacol Ther* 2008;119:1-6.
55. Schmidt LE, Ring-Larsen HR. Vasoconstrictor therapy for hepatorenal syndrome in liver cirrhosis. *Curr Pharm Des* 2006;12:4637-47.
56. Moreau R, Lebrech D. The use of vasoconstrictors in patients with cirrhosis: type 1 HRS and beyond. *Hepatology* 2006;43:385-94.
57. Ginès P, Guevara M. Therapy with vasoconstrictor drugs in cirrhosis: the time has arrived. *Hepatology* 2007;46:1685-7.
58. Guevara M, Ginès P, Fernández- Esparrach G, et al. Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion. *Hepatology* 1998;27:35-41.
59. Gülberg V, Bilzer M, Gerbes AL. Longterm therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine. *Hepatology* 1999;30:870-5.
60. Kiser TH, Fish DN, Obritsch MD, Jung R, MacLaren R, Parikh CR. Vasopressin, not octreotide, may be beneficial in the treatment of hepatorenal syndrome: a retrospective study. *Nephrol Dial Transplant* 2005;20:1813-20.
61. Moreau R, Durand F, Poynard T, et al. Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. *Gastroenterology* 2002;122:923-30.
62. Fabrizi F, Dixit V, Martin P. Metaanalysis: terlipressin therapy for hepatorenal syndrome. *Aliment Pharmacol Ther* 2006;24:935-44.
63. Gluud LL, Kjaer MS, Christensen E. Terlipressin for hepatorenal syndrome. *Cochrane Database Syst Rev* 2006;4: CD005162.
64. Sanyal AJ, Boyer T, Garcia-Tsao G, et al. A randomized, prospective, doubleblind, placebo-controlled study of terlipressin for type 1 hepatorenal syndrome. *Gastroenterology* 2008;134:1360-8.
65. Martín-Llahí M, Pépin MN, Guevara M, et al. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. *Gastroenterology* 2008;134:1352-9.
66. Angeli P, Volpin R, Gerunda G, et al. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. *Hepatology* 1999;29:1690-7.
67. Duvoux C, Zanditenas D, Hézode C, et al. Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: a pilot study. *Hepatology* 2002;36:374-80.
68. Wong F, Pantea L, Sniderman K. Midodrine, octreotide, albumin and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. *Hepatology* 2004;40:55-64.
69. Esraïlian E, Pantangco ER, Kyulo NL, Hu KQ, Runyon BA. Octreotide/midodrine therapy significantly improves renal function and 30-day survival in patients with type 1 hepatorenal syndrome. *Dig Dis Sci* 2007;52:742-8.
70. Ortega R, Ginès P, Uriz J, et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. *Hepatology* 2002;36:941-8.
71. Keller F, Heinze H, Jochimsen F, Passfall J, Schuppan D, Büttner P. Risk factors and outcome of 107 patients with decompensated liver disease and acute renal failure (including 26 patients with hepatorenal syndrome): the role of hemodialysis. *Ren Fail* 1995;17:135-46.
72. Capling RK, Bastani B. The clinical course of patients with type 1 hepatorenal syndrome maintained on hemodialysis. *Ren Fail* 2004;26:563-8.
73. Boyer TD. Transjugular intrahepatic portosystemic shunts: current status. *Gastroenterology* 2003;124:1700-10.
74. Mitzner SR, Stange J, Klammt S, et al. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial. *Liver Transpl* 2000;6:277-86.
75. Schepke M, Appenrodt B, Heller J, Zielinski J, Sauerbruch T. Prognostic factors for patients with cirrhosis and kidney dysfunction in the era of MELD: results of a prospective study. *Liver Int* 2006;26:834-9.
76. Alessandria C, Ozdogan O, Guevara M, et al. MELD score and clinical type predict prognosis in hepatorenal syndrome: relevance to liver transplantation. *Hepatology* 2005;41:1282-9.
77. Sort P, Navasa M, Arroyo V, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. *N Engl J Med* 1999;341:403-9.
78. Fernández J, Navasa M, Garcia-Pagan JC, et al. Effect of intravenous albumin on systemic and hepatic hemodynamics and vasoactive neurohormonal systems in patients with cirrhosis and spontaneous bacterial peritonitis. *J Hepatol* 2004;41:384-90.
79. Quinlan GJ, Martin GS, Evans TW. Albumin: biochemical properties and therapeutic potential. *Hepatology* 2005;41:1211-9.

80. Fernández J, Navasa M, Planas R, et al. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. *Gastroenterology* 2007;133:818-24.
81. Bernard B, Grangé JD, Khac EN, Amiot X, Opolon P, Poynard T. Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: a meta-analysis. *Hepatology* 1999;29:1655-61.
82. Fernández J, Ruiz del Arbol L, Gómez C, et al. Norfloxacin vs ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage. *Gastroenterology* 2006;131:1049-56.
83. Davis CL, Gonwa TA, Wilkinson AH. Identification of patients best suited for combined liver-kidney transplantation: part II. *Liver Transpl* 2002;8:193-211.
84. Restuccia T, Ortega R, Guevara M, et al. Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome: a case-control study. *J Hepatol* 2004;40:140-6.
85. Gonwa TA. Combined kidney liver transplant in the MELD era: where are we going? *Liver Transpl* 2005;11:1022-5.
86. Pawarode A, Fine DM, Thuluvath PJ. Independent risk factors and natural history of renal dysfunction in liver transplant recipients. *Liver Transpl* 2003;9:741-7.
87. 2000 Annual report of the U.S. Scientific Registry for Transplant Recipients and the Organ Procurement and Transplantation Network: transplant data 1990–1999. Rockville, MD: Department of Health and Human Services, 2000.
88. Pham PT, Pham PC, Wilkinson AH. Renal function outcomes following liver transplantation and combined liver-kidney transplantation. *Nat Clin Pract Nephrol* 2007;3:507-14.
89. Machicao VI, Srinivas TR, Hemming AW, et al. Impact of implementation of the MELD scoring system on the prevalence and incidence of chronic renal disease following liver transplantation. *Liver Transpl* 2006;12:754-61.
90. Locke JE, Warren DS, Singer AL, et al. Declining outcomes in simultaneous liver-kidney transplantation in the MELD era: ineffective usage of renal allografts. *Transplantation* 2008;85:935-42.
91. Davis CL, Feng S, Sung R, et al. Simultaneous liver-kidney transplantation: evaluation to decision making. *Am J Transplant* 2007;7:1702-9.
92. Campbell MS, Kotlyar DS, Brensinger CM, et al. Renal function after orthotopic liver transplantation is predicted by duration of pretransplantation creatinine elevation. *Liver Transpl* 2005;11:1048-55.
93. Marik PE, Wood K, Starzl TE. The course of type 1 hepatorenal syndrome post liver transplantation. *Nephrol Dial Transplant* 2006;21:478-82.
94. Jeyarajah DR, Gonwa TA, McBride M, et al. Hepatorenal syndrome: combined liver kidney transplants versus isolated liver transplant. *Transplantation* 1997;64:1760-5.
95. Ruiz R, Kunitake H, Wilkinson AH, et al. Long-term analysis of combined liver and kidney transplantation at a single center. *Arch Surg* 2006;141:735-42.
96. Simpson N, Cho YW, Ciciarelli JC, Selby RR, Fong TL. Comparison of renal allograft outcomes in combined liverkidney transplantation versus subsequent kidney transplantation in liver transplant recipients: analysis of UNOS database. *Transplantation* 2006;82:1298-303.
97. Demirci G, Becker T, Nyibata M, et al. Results of combined and sequential liverkidney transplantation. *Liver Transpl* 2003;9:1067-78. [Erratum, *Liver Transpl* 2004;10:329.]
98. Olausson M, Mjörnstedt L, Nordén G, et al. Successful combined partial auxiliary liver and kidney transplantation in highly sensitized cross-match positive recipients. *Am J Transplant* 2007;7:130-6.
99. Eason JD, Gonwa TA, Davis CL, Sung RS, Gerber D, Bloom RD. Proceedings of consensus conference on simultaneous liver kidney transplantation (SLK). *Am J Transplant* 2008;8:2243-51.